Pasireotide: A potential therapeutic alternative for resistant prolactinoma.

CONCLUSION: This is a promising first report of a patient with a DA-resistant macroprolactinoma who achieved long-term control, in terms of prolactin normalization and tumor volume, under pasireotide treatment alone. Pasireotide could thus be an alternative in prolactinomas resistant to DA. SSTR expression analysis on pathology could guide patient selection.
PMID: 30318256 [PubMed - as supplied by publisher]

Source: Annales d'Endocrinologie - September 25, 2018 Category: Endocrinology Authors: Lasolle H, Vasiljevic A, Borson-Chazot F, Raverot G Tags: Ann Endocrinol (Paris) Source Type: research